ABSTRACT

We reviewed the surgical treatment and outcomes of 13 patients with pelvic osteosarcoma treated in our centre in the past decade. The study sample included 9 males and 4 females with a mean age of 28.1 years. Four patients had ileal lesions, five had acetabulum lesions, one had a ischiopubis lesion, and three had involvement of the whole hemipelvis. Seven patients presented with distant metastases at diagnosis. Limb salvage was performed in 6 patients and amputation in 7. In 60% of cases in the limb salvage surgery group, we attempted wide resection with positive microscopic margin compared to only 16.7% in the amputation group. Local recurrence was higher in the limb salvage group. Overall survival was 18 months for mean follow up of 14.8 months. Median survival was 19 months in the limb salvage group compared to 9 months in amputation group. The outcome of surgical treatment of pelvic osteosarcoma remains poor despite advancements in musculoskeletal oncology treatment.

Key Words:
Pelvic osteosarcoma, limb salvage surgery, hemipelvectomy, margins, oncologic outcomes

INTRODUCTION

Pelvic osteosarcomas are rare, accounting for less than 10% of all osteosarcomas. Like other pelvic tumours, patients with pelvic osteosarcoma typically present at later stages with large tumour size; pulmonary metastases at the time of diagnosis are not uncommon. These tumours are in close proximity to the pelvic organs and neurovascular structures, and poor compartmentalization in the pelvis complicates attempts to achieve local control through adequate surgical margins. Histologically, pelvic osteosarcomas are usually chondroblastic in nature; similar to pelvic chondrosarcoma, such tumours respond poorly to chemotherapy and radiotherapy. Hence, surgical management of pelvic osteosarcoma is quite challenging and continues to be associated with significant mortality and morbidity despite advancement in multimodality treatment of musculoskeletal tumours.

Only a few large series of pelvic osteosarcomas surgical outcomes are available in the literature. Overall survival rates for pelvic osteosarcoma patients range from 20% to 50%, far worse than reported survival rates for osteosarcoma of the limbs. Since most reports are from single institutions, it is unclear whether the reported rates are universal for all pelvic osteosarcoma patients or specific to the respective institutions.

For almost two decades, in the Orthopaedic Oncology and Reconstruction Unit of Hospital Universiti Sains Malaysia, pelvic osteosarcomas have been treated with a multidisciplinary approach. We would like to review the treatment outcome of this condition.

MATERIALS AND METHODS

Thirteen patients with osteosarcoma of the pelvis were treated surgically from January 2001 to December 2010. Clinical and radiological records of all patients were reviewed. Routine haematological and biochemical investigation, magnetic resonance imaging (MRI) of the primary tumour, whole body technetium 99 bone scintigraphy and computed tomography (CT) of the chest were conducted as part of the staging workup. Tissue diagnoses were obtained in all cases with either open or true-cut biopsy.

Anatomic sites and types of resection were classified into type I (ilium), type II (acetabulum) and type III (ischio-pubis), or combinations thereof, based on the system established by Enneking and Dunham. Hemipelvic type is assigned when the tumour involves all three regions. Osteosarcomas of the sacrum and sacroiliac region were excluded from this study unless a majority of the tumour was located in the ilium based on radiological reports. Tumour volume was calculated according to the previously described methods. Tumour volume of > 1000ml were defined as...
large tumours, 500 to 1000ml were defined as moderate and < 500ml were defined as small tumours. Tumours were staged according to the Musculoskeletal Tumor Society (MSTS) staging system developed by Enneking15.

Patients received neoadjuvant chemotherapy consisting of adriamycin and cisplatinum according to the European Osteosarcoma Intergroup (EOI) protocol. Neoadjuvant chemotherapy was not prescribed in cases with chondroblastic subtype and those that required urgent surgical intervention to avoid delay. In patients who received neoadjuvant chemotherapy, surgery was performed after two to four cycles of chemotherapy. Repeat MRI evaluation for staging before surgery to assess response to chemotherapy and extent of primary tumour was performed two weeks before surgery. Limb salvage surgery (LSS) was attempted in most cases, but the final decision was made at the time of surgery and based on the ability to completely resect the tumour en bloc with preservation of the neurovascular bundle. Otherwise, patients were subjected to external hemipelvectomy. Various types of external hemipelvectomy were used based on the level of resection needed16. A classical hemipelvectomy or hindquarter amputation involves removal of the whole hemipelvis through the sacroiliac joint and pubic symphysis, together with the ipsilateral lower limb. A modified hemipelvectomy preserves part of the iliac crest. An extended hemipelvectomy consists of the standard procedure along with surgical removal of contiguous musculoskeletal structures, such as the lumbar spine, contralateral pelvic bones, or sacral elements. A compound hemipelvectomy involves resection of visceral pelvic structures in addition to the affected pelvic bone.

Wide resections consisting of tumour removal en bloc with a cuff of normal tissue around the mass were attempted in all patients with curative intent. For palliative cases, marginal resection was performed. Surgical specimens were evaluated for microscopic extension at tumour margins. Postoperatively, all patients, except for one with chondroblastic osteosarcoma, completed chemotherapy with or without radiotherapy. Patients were then assessed every three to four months. Repeat radiological assessment was performed when warranted, based on symptoms. Serial CT scans of the chest and whole body bone scans were performed every six months. Actuarial survivals of patients were estimated using Kaplan-Meier’s survival plots.

RESULTS

There were nine males and four females with a mean age of 28.1 years (range, 8-52 years). Tumours were located in the ilium/iliosacrum in four cases, acetabular region in five cases and in the ischiopubis in one case. The whole ipsilateral hemipelvis was involved in three cases. A majority presented with extracompartamental involvement with soft tissue infiltration (Stage IIB Enneking classification). Five patients had pulmonary metastases at the time of presentation. Three patients, all in stage III, had previous surgical treatment in other institutions and presented with local recurrence. All cases in this series were high-grade osteosarcoma. Eight cases (61.5%) were osteoblastic osteosarcoma and other subtypes included chondroblastic osteosarcoma, spindle cell osteosarcoma, fibrohistiocytic variant, fibroblastic osteosarcoma, and poorly-differentiated osteosarcoma (one case (7.7%) of each subtype).

Eight patients had large tumour volume, and the median volume was 1122.5ml (range, 19ml-4500ml). Limb salvage surgery was performed in six patients with three cases of type I resection, two type II resections and a single case of type III resection. Following type I resection, two cases need no further reconstruction; only one case was reconstructed with Galveston iliolumbar fusion with instrumentation and allograft (Figure 1a). The single case of type III resection did not require any further reconstruction as the hip joint was not involved (Figure 1c and 1d). Two patients that underwent type II resection received different types of reconstruction. In the first case, ischiofemoral arthrodesis was performed (Figure 1b), and the second patient was subjected to extracorporeal radiation followed by reconstruction with a modified Harrington procedure (Figure 1c and 1f). External hemipelvectomy was necessary in seven cases, five were external hemipelvectomies, and three others were one each of modified and extended type.

Wide resection was performed in all cases with curative intention; five cases in the LSS group and six cases in the amputation group. Marginal resection was performed in one case of type I palliative resection and another case of palliative amputation. Three out of five cases from the LSS group (60.0%) with attempted wide resection had positive microscopic margins compared to only one out of six (16.7%) in the amputation group (Table I). Local oncologic clearance was better achieved in stage III tumours and tumours with large volume.

Microscopic margins were negative in 7 patients; 4 cases of stage IIA and IIB were free of disease. Two cases of stage III survived with disease and 4 died of the disease. Six cases had positive microscopic margin; 4 cases of stage IIA and IIB survived without disease, one survived with disease and another died of the disease. Two cases of stage III survived with the disease at 12 months. Overall median survival time was 18 months for a mean follow up of 14.8 months (range 1-100 months). Median survival of the LSS group was 19 months compared to 9 months in the amputation group (Figure 2b). Only one amputee had local recurrence within the first post-surgery year compared to two cases from the LSS group. Both cases had positive microscopic margins.

The actual oncologic status of patients at the last follow-up in relation to stage of tumour, achieved surgical margin and
Table I: Stage of tumour, tumour volume, and achieved surgical margin

| Stage | n   | small | moderate | large | Surgical Margin | Microscopic margin |
|-------|-----|-------|----------|-------|-----------------|-------------------|
|       |     |       |          |       | w  | m  | -ve | +ve |
| IIA   | 1   | 1     | 0        | 0     | 1  | 0  | 1   | 0   |
| IIB   | 5   | 1     | 2        | 2     | 4  | 1  | 1   | 4   |
| III   | 7   | 1     | 0        | 6     | 6  | 1  | 5   | 2   |

W: Wide Resection, M: Marginal Resection

Table II: Oncologic outcome according to surgery types and microscopic margin

| Stage | n   | LSS | EH | +ve | -ve | NED | AWD | DOD | DWD |
|-------|-----|-----|----|-----|-----|-----|-----|-----|-----|
| IIA   | 1   | 1   | 0  | 0   | 1   | 1   | -   | -   | -   |
| IIB   | 5   | 3   | -  | 3   | 0   | 1   | 1   | 1   | -   |
| III   | 7   | 2   | -  | 1   | 1   | 2   | -   | -   | 2   |

LSS – limb salvage surgery, EH – external hemipelvectom y, NED – no evidence of disease, AWD – alive with disease, DOD – died of disease, DWD – died with disease.

Fig. 1: Anteroposterior plain radiographs of the pelvis. Galveston iliolumbar fusion following iliosacral resection (A). Ischiofemoral arthrodesis following ilioacetabular resection (B). Osteosarcoma of the pubic bone resection without reconstruction (C, D). Osteosarcoma involving the ipsilateral ischiopubis, acetabulum and ilium, resected and reconstructed with a modified Harrington procedure (E, F).
microscopic margin, and the types of surgical treatment is summarized in Table II. Two out of five patients with stage IIB osteosarcoma underwent amputation. Both had no evidence of recurrence on last follow-up. The patient who underwent type II resection followed by modified Harrington reconstruction had local recurrence after eight months and subsequently underwent external hemipelvectomy. She survived for almost nine month after the second surgery. The only patient with distant metastases who underwent LSS succumbed to the disease three months after surgery.

Two of four amputated patients survived with the disease for more than 1 year with the longest up to 31 months. The longest survivor was not responsive to chemotherapy and was diagnosed with secondary acute myeloid leukaemia (AML) two years after surgery. All amputees had local flap complications, including flap congestion, wound dehiscence and infection. A majority of patients (4 of 6) from the LSS group also had local wound complications.

Two LSS patients had neurological deficits after surgery. Complications seemed to be related to the types of surgery rather than age-related.

DISCUSSION

Although large series have been reported on pelvic osteosarcoma, information is still limited particularly for reported series from this global region. This makes comparison of the current series with others more difficult. Cases in the current series were slightly different than those previously reported. A majority of our cases were osteoblastic in nature and not chondroblastic. Therefore, most of our patients underwent neo-adjuvant chemotherapy. Classically, tumour size is used for staging and prognostication of tumours, and in fact, there is a trend now towards the use of tumour volume to predict the risk of metastases and prognosis. As such, we also used tumour volume to predict prognosis and metastases. The anatomical distribution of tumours in this study correlates with what was described by Enneking, in which the most common site is the iliosacral region.

Pelvic osteosarcomas are difficult to treat, even with the advancement of multimodal oncologic services. Excellent response to chemotherapy in the treatment of osteosarcoma assist surgeons to achieve adequate local control. Unfortunately, in pelvic osteosarcoma, there is typically a poor response to chemotherapy. Large tumour size or volume further decrease response to chemotherapy while at the same time making it difficult to resect without marked morbidity. Furthermore, the median age is higher for pelvic osteosarcoma patients compared to patients with extremity osteosarcoma, and therefore a lower chemotherapy dose intensity is used. Late presentation and large tumour mass is still a widespread problem among patients in this region especially since a large number of patients still opt for complementary-alternative medicine for orthopaedic problems before presenting to the medical center.

Misdiagnosis and late detection of pelvic tumours is still relatively common even among experienced surgeons. Since early 2000, osteosarcoma patients treated in our centre were subjected to chemotherapy according to European Osteosarcoma Intergroup (EOI) protocol. We use adriamycin and cisplatinum with additional ifosfamide if there is significant soft tissue involvement. Survival rates of patients
were evaluated in a short review in 2004 that showed an overall survival rate of 52%, and survival rate of 78% in the limb salvage group.

Randomized trials have demonstrated that the two-drug regimen has outcomes comparable to the multi-drug regimen incorporating methotrexate with a more complex and longer schedule. In a recent study using the combination of adriamycin, cisplatinum, and ifosfomide, there was a significant association between good responses and compliant patients. Hence, institutions with limited resources should endeavor to provide pharmacokinetic monitoring for methotrexate.

As expected, large volume tumour resistance to chemotherapy is associated with higher risk of pulmonary metastases, and both factors carry a very poor prognosis in pelvic osteosarcomas. Another important prognostic factor is the adequacy of tumour resection. Despite the growing trend towards LSS, previous reports showed amputation has a better rate of adequate surgical margins. Similarly, a majority of LSS patients in the current series had positive margins compared to amputation group (Table II). Previously, the probability of achieving a clear microscopic margin in pelvic resections with attempted wide resections was only 50%. Similar findings were reported in previous series. Thus, external hemipelvectomy should be selected in cases where LSS may compromise margin adequacy considering the high risk of local recurrence. Radiotherapy should be considered when adequate local control cannot be obtained from surgery. Due to the limited number of patients in the current series, we did not evaluate the association between anatomic site, tumour stage, and tumour volume with the incidence of positive microscopic margins following resection. Overall survival of patients in the current series is comparable to the lower end of rates reported in previous published series, between 20% and 50%.

CONCLUSION

External hemipelvectomy provided fairly good local control but was associated with significant morbidity. Hemipelvectomy is viable as a curative procedure for locally advanced osteosarcoma of the pelvis. Survival was influenced by the presence of pulmonary metastases as well as the status of microscopic margin. Technical challenges, infrequent indications for these procedures, and anticipated complications demands that resection of these tumours be performed only in highly specialized tertiary medical institutions with a comprehensive, multidisciplinary, surgical oncology team, and state-of-the-art facilities.
REFERENCES

1. Fahey M, Spanier S, Vander Griend R. Osteosarcoma of the pelvis. A clinical and histopathological study of twenty-five patients. J Bone Joint Surg Am. 1992; 74(3): 321-30.

2. Unni KK. Dahlin's bone tumors: general aspects and data on 11,087 cases. 5th ed. Philadelphia, New York: Lippincott-Raven; 1996.

3. Isakoff MS, Barkauskas DA, Ebb D, Morris C, Letson GD. Poor survival for osteosarcoma of the pelvis: a report from the Children's Oncology Group. Clin Orthop Relat Res. 2012; 470(7): 2007-13.

4. Ham SJ, Kroon HM, Koops HS, Hoekstra HI. Osteosarcoma of the pelvis—oncological results of 40 patients registered by The Netherlands Committee on Bone Tumours. Eur J Surg Oncol. 2000; 26(1): 53-60.

5. Kawai A, Huvos AG, Meyers PA, Healey JH. Osteosarcoma of the Pelvis: Oncologic Results of 40 Patients. Clin Orthop Relat Res. 1998; 348:196-207.

6. Donati D, Giacomini S, Gozzi E, Ferrari S, Sangiorgi L, Tienghi A, et al. Osteosarcoma of the pelvis. Eur J Surg Oncol. 2004; 30(3): 332-40.

7. Saab R, Rao BN, Rodriguez-Galindo C, Billups CA, Fortenberry TN, Daw NC. Osteosarcoma of the pelvis in children and young adults: the St. Jude Children's Research Hospital experience. Cancer. 2005; 103(7): 1468-74.

8. Grimer RJ, Carter SR, Tillman RM, Spooner D, Mangham DC, Kabukcuoglu Y. Osteosarcoma of the pelvis. J Bone Joint Surg Br. 1999; 81-B(5): 796-802.

9. Bielack SS, Wulff B, Delling G, Gobel U, Kotz R, Ritter J, et al. Osteosarcoma of the trunk treated by multimodal therapy: experience of the Cooperative Osteosarcoma study group (COSS). Med Pediatr Oncol. 1995; 24(1): 6-12.

10. Renard AJ, Veth RP, Schreuder HW, Pruszczynski M, Bokkerink JP, van Hoesel QG, et al. Osteosarcoma: oncologic and functional results. A single institutional report covering 22 years. J Surg Oncol. 1999; 72(3):124-9.

11. Enneking WF, Dunham WK. Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am. 1978; 60(6): 731-46.

12. Moon SH, Shin KH, Suh JS, Yang WI, Noh JK, Hahn SB. Tumor volume change after chemotherapy as a predictive factor of disease free survival for osteosarcoma. Yonsei Med J. 2005; 46(1): 119-24.

13. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996; 14(3): 848-58.

14. Abuda A, Davies AM, Pynsent PB, Mangham DC, Tillman RM, Carter SR, et al. Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma. J Bone Joint Surg Br. 1999; 81-B(2): 317-22.

15. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993; 286: 241-6.

16. Senchenkov A, Moran S, Petty P, Knoetgen J, Clay R, Bite U, et al. Predictors of Complications and Outcomes of External Hemipelvectomy Wounds: Account of 160 Consecutive Cases. Ann Surg Oncology. 2008; 15(1): 355-63.

17. Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling Gn, et al. Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2003; 21(2): 334-41.

18. Fuchs B, Hoekzema N, Larson DR, Inwards CY, Sim FH. Osteosarcoma of the Pelvis. Outcome Analysis of Surgical Treatment. Clin Orthop Relat Res. 2009(467): 510-8.

19. Matsuo T, Sugita T, Sato K, Hotta T, Tsuchiya H, Shimose S, et al. Clinical Outcomes of 54 Pelvic Osteosarcomas Registered by Japanese Musculoskeletal Oncology Group. Oncology. 2005; 68(4-6): 375-81.

20. Munajat I, Zulmi W, Norazman MZ, Wan Faisham WI. Tumour volume and lung metastasis in patients with osteosarcoma. J Orthop Surg (Hong Kong). 2008; 16(2): 182-5.

21. Enneking W, Dunham W. Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am. 1978; 60(6): 731-46.

22. Bielack SS, Kempf-Bielack B, Delling Gn, Exner GU, Flege S, Helmke K, et al. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol. 2002; 20(3): 776-90.
23. Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. *Clin Orthop Relat Res.* 2000(376): 200-8.

24. Kawai A, Healey JH, Boland PJ, Lin PP, Huvos AG, Meyers PA. Prognostic factors for patients with sarcomas of the pelvic bones. *Cancer.* 1998; 82(5): 851-9.

25. Omololu B, Ogunlade SO, Alonge TO. The complications seen from the treatment by traditional bonesetters. *West Afr J Med.* 2002; 21(4): 335-7.

26. Bickels J, Kahanovitz N, Rubert CK, Henshaw RM, Moss DP, Meller I, et al. Extraspinal bone and soft-tissue tumors as a cause of sciatica. Clinical diagnosis and recommendations: analysis of 32 cases. *Spine (Phila Pa 1976).* 1999; 24(15): 1611-6.

27. Thompson RC, Jr., Berg TL. Primary bone tumors of the pelvis presenting as spinal disease. *Orthopedics.* 1996; 19(12): 1011-6.

28. Kleiner JB, Donaldson WF, 3rd, Curd JG, Thorne RP. Extraspinal causes of lumbosacral radiculopathy. *J Bone Joint Surg Am.* 1991; 73(6): 817-21.

29. Wurtz LD, Peabody TD, Simon MA. Delay in the Diagnosis and Treatment of Primary Bone Sarcoma of the Pelvis. *J Bone Joint Surg Am.* 1999; 81(3): 317-25.

30. Faisham WI, Zulmi W, Halim AS, Biswal BM, Mutum SS. Osteosarcoma: the outcome of limb salvage surgery. *Med J Malaysia.* 2004; 59 Suppl F: 24-34.

31. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. *Cancer.* 1982; 49(6): 1221-30.

32. Bramwell VHC, Burgers MV, Souhami RL, Taminiau AHM, Eijken JWVD, Craft AW, et al. A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: a study of the European Osteosarcoma Intergroup. *Sarcoma.* 1997; 1(3/4): 155.

33. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. *Lancet.* 1997; 350(9082): 911-7.

34. Bajpai J, Puri A, Shah K, Susan D, Jambhekar N, Rekhi B, et al. Chemotherapy compliance in patients with osteosarcoma. *Pediatr Blood Cancer.* 2013; 60(1): 41-4.

35. Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, et al. Frontline treatment of localized osteosarcoma without methotrexate. *Cancer.* 2011; 117(12): 2770-8.

36. Cartiaux O, Docquier P-L, Paul L, Francq BG, Cornu OH, Delloye C, et al. Surgical inaccuracy of tumor resection and reconstruction within the pelvis: An experimental study. *Acta Orthop.* 2008; 79(5): 695-702.